Novartis CEO Touts R&D 'Wild Cards' As Proof Of Deep Pipeline
Multi-Billion Dollar Opportunities In Development
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
